Scholar Rock Holding Corporation (SRRK) Cash Flow Statement

The OCF/NI ratio has deteriorated from 0.88x in 2024Q1 to 0.63x in 2026Q2, meaning cash outflows are growing faster than accounting losses. This suggests that non-cash charges like stock-based compensation, which rose from $8.2M to $19.7M per quarter, are becoming a larger offset to cash burn. Investors should monitor whether this divergence signals aggressive expense recognition or a genuine acceleration in cash-intensive clinical trial spending.

The FCF trajectory shows a clear upward burn trend, with quarterly outflows expanding from roughly $50M to nearly $70M over the ten-quarter period. This acceleration aligns with the completion of enrollment in the Phase 3 SAPPHIRE trial, which likely increased clinical and manufacturing costs. Without product revenue, the company's cash runway is directly tied to this burn rate, and the lack of guidance in the latest earnings report suggests management may be uncertain about near-term financing needs.

Capex is essentially immaterial, with quarterly spending never exceeding $271K, indicating that the company's cash burn is driven almost entirely by operating expenses rather than fixed asset investment. This is typical for a clinical-stage biotech that outsources manufacturing and relies on third-party facilities. The lack of capex suggests that future commercial manufacturing will require significant capital commitments, which are not yet reflected in the cash flow statement.

The working capital adjustments are small relative to the overall burn, but they show quarter-to-quarter volatility that can distort single-period cash flow comparisons. For instance, 2025Q1 saw a -$17.5M working capital drag, while 2025Q3 saw a +$17.5M benefit, likely reflecting timing of clinical trial vendor payments and milestone receipts. These swings are not indicative of operational efficiency but rather the lumpy nature of pre-revenue biotech cash flows.

Capital deployment is entirely focused on funding clinical development, with zero returns to shareholders. This is consistent with a company in the burn phase, but it also means that any future financing will be fully dilutive to existing shareholders. The absence of buybacks or dividends is not a concern for a clinical-stage biotech, but it underscores the reliance on external capital to reach commercialization.

The cumulative gap between net income and operating cash flow is substantial, driven primarily by stock-based compensation, which totaled approximately $150M over the period. This means that accounting losses overstate the actual cash drain, but the remaining cash burn is still significant. Investors should recognize that the company's true cash runway is longer than the net loss suggests, but the gap is narrowing as SBC grows relative to total losses, which may indicate a shift toward more cash-intensive spending.